— Know what they know.
Not Investment Advice
Also trades as: VIMIAN.ST (STO) · $vol 2M

VIMGF OTC

Vimian Group AB (publ)
1W: +0.0% 1M: +0.0% 3M: +0.0% YTD: +0.0% 1Y: -8.0%
$2.77
+0.00 (+0.00%)
 
OTC · Healthcare · Medical - Diagnostics & Research · Tech Score Strong Sell · Power 45 · $1.5B mcap · 163M float · 0.0028% daily turnover · Short 100% of daily vol
Smart Money Score
No convergence signal
Key Statistics
Market Cap$1.5B
52W Range2.68-3.01
Volume7,000
Avg Volume4,589
Beta1.19
Dividend—
Analyst Ratings
1 Buy 1 Hold 0 Sell
Consensus Buy
Company Info
CEOAlireza Tajbakhsh
Employees1,300
SectorHealthcare
IndustryMedical - Diagnostics & Research
IPO Date2022-08-22
Websitevimian.com
Riddargatan 19
Stockholm, AB 11457
SE
46 7 36 26 88 86
About Vimian Group AB (publ)

Vimian Group AB (publ) is an international enterprise focused on the animal health sector, organized into four distinct divisions: Specialty Pharma, MedTech, Diagnostics, and Veterinary Services. The company offers a range of proprietary diagnostic tools and treatments under its Nextmune brand, providing both prescription and non-prescription options for the preventive care and management of chronic conditions in companion animals. Through its Indical Bioscience brand, Vimian delivers sophisticated molecular and immunodiagnostic solutions for laboratories, specifically targeting veterinary applications for both livestock and companion animal health markets. Moreover, its VetFamily brand operates a membership-based platform that provides veterinary clinics with procurement services, tech-enabled operations including online marketing, education, and HR support, as well as a professional community. The company also supplies orthopedic implants to veterinarians and universities through its Movora brand. Established in 2020, Vimian Group is based in Stockholm, Sweden.

Recent Insider Trades

No insider trades found

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms